MEMarawan Saber Attia Elkaramany

Marawan Saber Attia Elkaramany

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Marawan Saber Attia Elkaramany has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Real-world Clinical Outcomes in Patients Receiving Zotarolimus-eluting Stents versus Non-zotarolimus-eluting Stents for Percutaneous Coronary Intervention

    by Jonathan Ong Wei Sheng, Muhammad Bin Idu Jion, Keh Yann Shan, Marawan Saber Attia Elkaramany, Gao Fei, Ningyan Wong, Jonathan Jiunn Liang Yap, Chin Chee Yang, Jiang Ming Fam, Kay Woon Ho, et al.

    Background: Current-generation zotarolimus-eluting stents (ZES) have been shown to be an effective choice for percutaneous coronary intervention. However, data comparing real-world clinical outcomes between ZES and other stent platforms (non-ZES) are limited. We aim to compare real-world clinical outcomes of patients receiving ZES versus non-ZES during percutaneous coronary intervention based on our centre’s registry. Methods: This was a non-randomised, non-blinded, all-comers observational registry comparing clinical outcomes in patients treated with ZES versus non-ZES (control). The primary endpoint of our study was defined as major adverse cardiac events, which was a composite of cardiac mortality, target vessel failure and MI at 1 year. Results: Within the study period, 526 patients fulfilled inclusion criteria (ZES: 218, controls: 308). Characteristics and procedural data of both groups were similar. Our study showed no significant differences in major adverse cardiac events between the ZES and control groups (3.2% versus 3.9%; HR 0.82; 95% CI [0.32–2.09]; p=0.68). Comparing clinical outcomes of ZES and control groups, there were similar rates of all-cause mortality (1.4% versus 2.3%; HR 0.60; 95% CI [0.16–2.33]; p=0.46) and MI (0.5% versus 1.0%; HR 0.47; 95% CI [0.049–4.49]; p=0.51). There were low rates of stent-related complications and no differences in target vessel revascularisation (1.4% versus 0.7%; HR 2.12; 95% CI [0.36–12.7]; p=0.41) and target vessel failure (1.4% versus 0.7%; HR 2.12; 95% CI [0.36–12.7]; p=0.41) between the ZES and control groups. Conclusion: Our study showed no significant differences in clinical outcomes between patients receiving ZES and those receiving non-ZES.